www.bethelfinance.com
Bethel Finance news:
Flowsense Medical Ltd. (TASE: FLSN) today announced successful preliminary findings that its Urinfo 2000 urine monitor can indicate the development of acute kidney failure within days following cardiac surgery. The medical team advises routinely using the device during cardiac surgey.
The Johns Hopkins University School of Medicine has successfully completed the first stage of its study of the monitor on 30 patients, to test whether continuous urine monitoring during cardiac surgery can provide early detection of acute kidney injury, thereby preventing it.
Lead research, Dr. Nevin Katz, a cardiologist said that Johns Hopkins plans to continue the study on 20 additional patients, and publish the official results.
Flowsense added that treatment costs of patients who develop acute kidney failure after surgery are much higher than patients who do not develop the problem, and that that their mortality rates are much higher.
Flowsense's share price rose 17% by early afternoon to NIS 0.09, giving a market cap of NIS 17 million.
No comments:
Post a Comment